Inflazyme Pharmaceuticals Ltd.

Inflazyme Pharmaceuticals Ltd.

Inflazyme Pharmaceuticals Ltd. is a biopharmaceutical company
focused on the discovery, development and commercialization of
therapies to treat serious inflammatory diseases including
asthma, rheumatoid arthritis, psoriasis and inflammatory bowel
disease. The company commenced operations in 1992 to further
develop technologies discovered by scientists at the University
of British Columbia and is now developing a number of
technologies based on its own internal discovery efforts.
Inflazyme is listed on The Toronto Stock Exchange under the
symbol IZP.

Company Details

Year Established: 1991

Number of Employees: 35

Company Information

Pat Bramley
Title: Office Manager
Telephone: (604) 279-8511
Fax: (604) 279-8711
Email: Click Here

Jeffrey Bacha
Title: Vice President
Area of Responsibility: Domestic Sales & Marketing
Telephone: (604) 279-8511
Fax: (604) 279-8711
Email: Click Here

Ian Mcbeath
Title: Chief Executive Officer
Area of Responsibility: Management Executive
Telephone: (604) 279-8511
Fax: (604) 279-8511
Email: Click Here

Kristie Campbell
Title: Executive Assistant
Telephone: (604) 279-8511
Email: Click Here

Products

Ipl 423 And Ipl 423,323

H1/Nk1
H1/NK1 Dual Antagonists H1/NK1 dual antagonists are a novel class of compounds developed by scientists at Hoechst Marion Roussel and licensed to Inflazyme. H1/NK1 dual antagonists combine, in a single molecule, an antihistamine and a neuro-peptide inhibitor. In pre-clinical studies to date, H1/NK1 dual antagonist compounds have demonstrated antagonist activity at both the H1 and NK1 receptors, which indicates that they may have the potential to relieve both the itchiness and the congestion associated with allergies. Inflazyme is developing H1/NK1 dual antagonists for the treatment of allergies in collaboration with Hoechst Marion Roussel, a world leader in pharmaceutical healthcare. Under the terms of the collaboration, Inflazyme has been granted a license to develop H1/NK1 dual antagonists through Phase IIa clinical trials. After Phase IIa trials are completed, Hoechst Marion Roussel will have the option to acquire exclusive worldwide rights to an oral dosage form of a product developed from the H1/NK1 dual antagonists upon payment of a milestone to Inflazyme. Hoechst Marion Roussel will then be responsible for further development and commercialization of the product. Inflazyme will retain rights to any topical ocular formulation of H1/NK1 dual antagonists.

Tb Diagnostic
TB-Diagnostics In addition to Inflazymes therapeutic product development portfolio, Inflazyme recently regained the rights to a tuberculosis diagnostics technology that had been licensed to Cortecs Diagnostics Ltd. Under the agreement, Cortecs had developed a prototype laboratory based TB diagnostic product. Inflazyme is currently reviewing what further work is necessary to progress this technology and plans to seek a potential new partner to be responsible for the development and commercialization of this technology.

Ipl 576 And Ipl 576,092
IPL576 Series and IPL576,092 IPL576,092 is Inflazymes lead clinical candidate from its novel IPL576 series of compounds. The IPL576 series is based on a molecule originally isolated from a sea sponge by researchers at the University of British Columbia and the University of Alberta. IPL576 has been patented in the US. Patents have been filed in Canada, the European Community, Japan and Australia. Inflazyme has exclusive license to the patents. Subsequent research has led to the filing of additional patents, which broaden the scope of Inflazymes intellectual property portfolio. Inflazyme has demonstrated that IPL576,092 has a significant effect on mediators of inflammation in vitro and in standard pre- clinical in vivo studies of asthma when administered orally or by inhalation. These pre-clinical studies demonstrate that IPL576,092 may have the efficacy of inhaled glucocorticoids without the related side effects. Inflazyme initiated Phase I human clinical trials with IPL576,092 in June 1999. The Company expects to receive interim results of its Phase I studies during Fall 1999 and final Phase I results in early 2000. IPL576 is being developed for the treatment of asthma and respiratory disease in collaboration with Hoechst Marion Roussel, a world leader in pharmaceutical healthcare. Under the terms of the collaboration, Inflazyme is responsible for the development of IPL 576 through Phase IIa clinical trials. After Phase IIa trials are completed, Hoechst Marion Roussel will have the option to acquire exclusive world-wide rights (non-exclusive in Canada) to an oral dosage form of a product developed from IPL576 series for the treatment of asthma and respiratory disease upon payment of a milestone to Inflazyme. Hoechst Marion Roussel will then be responsible for further development and commercialization of the product. Inflazyme is currently exploring other anti-inflammatory indications for IPL576 and expects to define an additional therapeutic project from this class of compounds during 1999. Hoechst Marion Roussel has a first right of refusal to license additional products developed from such projects on commercial terms to be agreed.

Services